Prepare a pathology-based summary of the topic Von Willebrand disease, explaining the cause, pathogenesis, clinical features, lab test findings, any peripheral smear findings, the types, sources of von Willebrand factor, a short summary of treatment required for NEET-PG 2026. This should help me answer almost 100% of questions that come from the pathology aspect of von Willebrand disease. It should also give the reason for a particular statement such that I don't have to mug it up, I can understand it, but it should be short and precise.
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Loading Image
Loading Image
I now have all the content needed to write a comprehensive, NEET-PG focused summary. Let me compile it:
Von Willebrand Disease (VWD) — Pathology Summary for NEET-PG 2026
1. Basics & Inheritance
- Most common inherited bleeding disorder (prevalence ~1% of the general population; clinically significant bleeding ~1:10,000)
- Autosomal dominant (most types); Type 3 is autosomal recessive
- Affects both sexes equally (autosomal) — key distinguisher from hemophilia (X-linked)
- Gene: chromosome 12 (vWF gene)
2. Sources of vWF
vWF is synthesized and stored in two places:
| Source | Storage Granule | Released by |
|---|---|---|
| Vascular endothelial cells (primary source) | Weibel-Palade bodies | Thrombin, DDAVP, shear stress |
| Megakaryocytes / Platelets | α-granules | Platelet activation |
Why it matters: DDAVP works by triggering endothelial release from Weibel-Palade bodies — this is why it helps in Type 1 (mild) VWD but NOT in Type 3 (no vWF to release).
3. Normal Functions of vWF
vWF has two critical roles:
- Platelet adhesion: vWF binds exposed subendothelial collagen at sites of injury, then acts as a bridge to platelet GpIb receptor → platelet adhesion (primary hemostasis)
- Carrier/chaperone for Factor VIII: vWF binds and protects Factor VIII from premature degradation in plasma; when vWF is deficient, Factor VIII gets rapidly cleared → reduced Factor VIII levels
Why vWF deficiency causes prolonged bleeding time: Loss of platelet adhesion (GpIb–vWF–collagen axis). This is a primary hemostasis defect, hence mucosal bleeding predominates.
4. Pathogenesis
Mutations in the vWF gene → either:
- Reduced quantity of vWF (quantitative defect — Types 1 & 3), or
- Structurally/functionally abnormal vWF (qualitative defect — Type 2)
Since vWF also carries Factor VIII, low vWF → secondary reduction in Factor VIII → secondary coagulation defect (usually mild; severe only in Type 3).
5. Clinical Features
| Feature | Reason |
|---|---|
| Mucocutaneous bleeding (epistaxis, gum bleeding, GI bleed, heavy menses) | Primary hemostasis defect — platelet plug formation fails |
| Easy bruising | Same mechanism |
| Prolonged bleeding after cuts/surgery | Failure of platelet adhesion + mildly reduced FVIII |
| Menorrhagia | Very common presenting complaint in females |
| Hemarthrosis / deep muscle hematoma | Rare; only in Type 3 (severe FVIII deficiency — mimics hemophilia A) |
The bleeding pattern is mucocutaneous (like thrombocytopenia/platelet disorders) — NOT deep tissue/hemarthrosis (which is coagulation disorder pattern) — except in Type 3 where FVIII is severely reduced.
6. Types of VWD
Type 1 — Partial Quantitative Deficiency (Most common — 75% of cases)
- Autosomal dominant
- Reduced quantity of vWF, but structurally normal; entire multimer spectrum present but in decreased amounts
- Mildly decreased Factor VIII
- Mild bleeding symptoms
- Responds well to DDAVP
Type 2 — Qualitative Defects (Abnormal vWF)
| Subtype | Defect | HMWMs | RIPA (low dose ristocetin) | Key Feature |
|---|---|---|---|---|
| 2A | Decreased synthesis OR increased proteolysis of HMWMs | Absent | Decreased/Absent | Decreased function; decreased ratio vWF:RCo/vWF:Ag <0.6 |
| 2B | Gain-of-function mutation → vWF binds GpIb too avidly | Absent (consumed) | Increased (aggregation at low dose ~0.3–0.5 mg/mL) | Mild thrombocytopenia (platelets consumed by spontaneous aggregation); most dangerous subtype — DDAVP contraindicated |
| 2M | Loss-of-function mutation in platelet-binding site | Present (normal) | Decreased | Normal multimer pattern but decreased function |
| 2N (Normandy) | Mutation in vWF's FVIII-binding site | Normal | Normal | Markedly low Factor VIII despite normal vWF antigen — mimics hemophilia A; autosomal inheritance distinguishes it |
Memory hook for 2B: "B = Binds Better" → vWF is hyperactive → consumes HMWMs and platelets → thrombocytopenia. Memory hook for 2N: "N = No FVIII binding" → FVIII is unprotected → rapidly destroyed → looks like Hemophilia A, but autosomal.
Type 3 — Severe/Complete Quantitative Deficiency
- Autosomal recessive (homozygous)
- Near-complete absence of vWF
- Severely low Factor VIII (because no carrier protein)
- Clinically resembles hemophilia A — hemarthrosis, deep hematomas
- Does NOT respond to DDAVP (no vWF to release)
- Requires Factor VIII concentrate or vWF-containing concentrates
7. Laboratory Findings
Screening Tests
| Test | Result in VWD | Reason |
|---|---|---|
| Bleeding Time (BT) | Prolonged | Platelet adhesion defect |
| Platelet count | Usually normal (↓ in Type 2B) | Not thrombocytopenic (except 2B) |
| PT | Normal | Extrinsic pathway unaffected |
| aPTT | Normal or mildly prolonged | FVIII is mildly reduced; prolonged notably in Type 3 and 2N |
| Platelet function analyzer (PFA-100) | Prolonged closure time | Sensitive test for platelet adhesion defects |
Classic VWD lab pattern: Normal platelet count + Prolonged BT + Normal PT + Normal or slightly prolonged aPTT. If aPTT is markedly prolonged → Type 3 or Type 2N.
Specific/Confirmatory Tests
| Test | What it measures | Findings |
|---|---|---|
| vWF antigen (vWF:Ag) | Total vWF protein (quantity) | Decreased in Types 1, 3; Normal in 2N, 2M |
| Ristocetin cofactor activity (vWF:RCo) | vWF function — ability to bind platelet GpIb | Decreased in most types |
| vWF:RCo / vWF:Ag ratio | Functional adequacy of vWF | <0.6 in Type 2A, 2B; normal in Type 1 and 3 |
| Factor VIII activity (FVIII:C) | FVIII level | Mildly ↓ in Types 1 & 2; markedly ↓ in Type 3 & 2N |
| Ristocetin-induced platelet aggregation (RIPA) | Platelet aggregation with ristocetin | ↑ at low dose in Type 2B; ↓/absent in 2A and 2M |
| vWF multimer analysis (SDS-agarose gel electrophoresis) | Size distribution of vWF multimers | Gold standard for subtyping Type 2; absence of HMWMs in 2A and 2B |
| vWF:FVIII binding assay | vWF's ability to bind Factor VIII | Markedly decreased in Type 2N |
Ristocetin is an antibiotic that mimics exposed subendothelium — it forces vWF to bind platelet GpIb. If vWF is absent or dysfunctional, platelets fail to aggregate. In Type 2B, even tiny amounts of ristocetin trigger aggregation because the vWF is hyperactive.
Peripheral Blood Smear
- Usually normal
- Platelet morphology is normal (VWD is a plasma protein defect, not a platelet structural defect)
- Mild thrombocytopenia may be seen in Type 2B (from platelet consumption), but platelets appear morphologically normal
- No schistocytes, no giant platelets (distinguishes from BSS/TTP)
8. Differentiating VWD from Hemophilia A
| Feature | VWD (Type 1/2) | Hemophilia A |
|---|---|---|
| Inheritance | Autosomal dominant | X-linked recessive |
| Sex | Both sexes | Males primarily |
| Bleeding type | Mucocutaneous | Deep (hemarthrosis, muscle) |
| BT | Prolonged | Normal |
| PT | Normal | Normal |
| aPTT | Normal or mildly prolonged | Prolonged |
| FVIII | Mildly reduced | Markedly reduced |
| vWF:Ag | Reduced | Normal |
| RIPA | Reduced | Normal |
Type 2N VWD exception: Presents like Hemophilia A (↑↑ aPTT, markedly low FVIII) but BT is prolonged and inheritance is autosomal — these two features point away from hemophilia.
9. Treatment
| Situation | Treatment | Mechanism |
|---|---|---|
| Type 1 (mild-moderate), pre-procedure | DDAVP (desmopressin) IV/intranasal | Releases vWF from endothelial Weibel-Palade bodies → acute rise in vWF and FVIII |
| Type 3, severe Type 1, major surgery | vWF-containing Factor VIII concentrates (e.g., Humate-P, Alphanate) | Replaces deficient vWF directly |
| Type 2B | DDAVP is CONTRAINDICATED | Would release more abnormal hyperactive vWF → worsens thrombocytopenia via platelet consumption |
| Adjunct | Tranexamic acid / ε-aminocaproic acid | Antifibrinolytics — stabilize clot; useful for mucosal bleeding |
| Menorrhagia | Oral contraceptives + tranexamic acid | Estrogens increase vWF levels |
| Type 2N / hemophilia-like | Factor VIII concentrate + vWF | Replaces both deficient factors |
Why DDAVP works: It is a vasopressin analogue that acts on V2 receptors on endothelial cells, triggering exocytosis of Weibel-Palade bodies → releases stored vWF and tPA. Why cryoprecipitate is used: Contains high concentration of vWF, FVIII, fibrinogen — older option, still used when concentrates unavailable.
10. High-Yield One-Liners for NEET-PG
- Most common inherited bleeding disorder = VWD (not hemophilia)
- vWF stored in: Weibel-Palade bodies (endothelium) + α-granules (platelets)
- vWF links platelets to collagen via: GpIb receptor
- Classic lab: Normal platelet count + Prolonged BT + Normal PT + Normal/slightly prolonged aPTT
- Type 2B = gain-of-function + HMWMs absent + thrombocytopenia + increased RIPA at low dose ristocetin
- Type 2N = mimics Hemophilia A + autosomal + normal vWF:Ag + normal RIPA + markedly low FVIII
- DDAVP contraindicated in Type 2B (worsens thrombocytopenia)
- Type 3 = most severe + autosomal recessive + mimics Hemophilia A + requires FVIII/vWF concentrate
- Peripheral smear = normal (no schistocytes, no giant platelets)
- Blood group O individuals have ~25% lower vWF levels — can simulate Type 1 VWD
- Acquired VWD — causes: aortic stenosis (shear stress destroys HMWMs), lymphoproliferative disorders (antibodies), hypothyroidism (decreased synthesis)
- Ristocetin → tests vWF–GpIb axis; absent aggregation in VWD; hyperaggregation at LOW dose in Type 2B
Sources: Robbins & Kumar Basic Pathology, 11e; Henry's Clinical Diagnosis and Management by Laboratory Methods, 24e; Tietz Textbook of Laboratory Medicine, 7e
This is a shared conversation. Sign in to Orris to start your own chat.